Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 463 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Biogen Clear all
Completed Phase 1Phase 2 Interventional

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

NCT00107861
View directory record Official record
Conditions
Colorectal Carcinoma, Metastases
Interventions
Ad.hIFN-β (BG00001, IDEC-201)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
La Jolla, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease

NCT03318523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Placebo, BIIB054
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers

NCT05216887
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Aducanumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 70 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated Phase 2 Interventional Results available

A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

NCT05895552
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RTA 901, RTA 901-Matching Placebo
Drug
Lead sponsor
Reata, a wholly owned subsidiary of Biogen
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
75
States / cities
Mesa, Arizona • Phoenix, Arizona • Canoga Park, California + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How BIIB141 (Omaveloxolone) is Processed in the Body When Taken as Capsules Compared to Sprinkled on Yogurt in Healthy Adults Aged 18 to 55

NCT07019064
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 17, 2026, 8:43 AM EDT
Completed No phase listed Observational

JC Virus Reactivation in Multiple Sclerosis

NCT02004444
View directory record Official record
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 3 Interventional

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

NCT03584165
View directory record Official record
Conditions
Choroideremia, X-Linked Retinitis Pigmentosa
Interventions
BIIB111, BIIB112
Genetic
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
18 Years and older · Male only
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 17, 2026, 8:43 AM EDT
Completed No phase listed Observational

Natural Disease Progression in Participants With Choroideremia

NCT04795206
View directory record Official record
Conditions
Choroideremia
Interventions
No Intervention
Other
Lead sponsor
Biogen
Industry
Eligibility
10 Years and older
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation

NCT01646840
View directory record Official record
Conditions
Healthy
Interventions
PF-04958242 capsule, PF-04958242 oral solution
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT00099489
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Interferon Beta-1a
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

NCT03870763
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Dimethyl Fumarate, Peginterferon Beta-1a, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

NCT02484547
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab (BIIB037), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis

NCT02219932
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
fampridine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated No phase listed Observational

Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis

NCT03926637
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Multiple Sclerosis Performance Test (MSPT)
Other
Lead sponsor
Biogen
Industry
Eligibility
Not listed
Enrollment
3,073 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
22
States / cities
Berkeley, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 3 Interventional Results available

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1

NCT02634307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ALKS 8700
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
74
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1Phase 2 Interventional

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT00103558
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lumiliximab with FCR
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033, Placebo, Avonex
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

NCT01689116
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bardoxolone Methyl 20mg, Bardoxolone Methyl 80mg, Bardoxolone Methyl Placebo, Moxifloxacin 400mg, Moxifloxacin Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Formulation and Food Effect Study of BIIB074

NCT02951221
View directory record Official record
Conditions
Trigeminal Neuralgia (TN), Other Neuropathic Pain
Interventions
BIIB074 Treatment A, BIIB074 Treatment B, BIIB074 Treatment C, BIIB074 Treatment D
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 17, 2026, 8:43 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565
View directory record Official record
Conditions
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
62
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults

NCT06454721
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[89Zr]Zr-DFO-Diranersen, Diranersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 17, 2026, 8:43 AM EDT
Completed Phase 2 Interventional

Alefacept Mechanism of Action in Psoriasis

NCT00150982
View directory record Official record
Conditions
Psoriasis
Interventions
Mechanism of action of alefacept
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 17, 2026, 8:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 8:43 AM EDT